"Hepatocyte Growth Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Multifunctional growth factor which regulates both cell growth and cell motility. It exerts a strong mitogenic effect on hepatocytes and primary epithelial cells. Its receptor is PROTO-ONCOGENE PROTEINS C-MET.
Descriptor ID |
D017228
|
MeSH Number(s) |
D12.644.276.374.420 D12.776.467.374.420 D23.529.374.420
|
Concept/Terms |
Hepatocyte Growth Factor- Hepatocyte Growth Factor
- Factor, Hepatocyte Growth
- Growth Factor, Hepatocyte
- Scatter Factor
- Factor, Scatter
- Hepatopoietin
- Hepatopoietin A
|
Below are MeSH descriptors whose meaning is more general than "Hepatocyte Growth Factor".
Below are MeSH descriptors whose meaning is more specific than "Hepatocyte Growth Factor".
This graph shows the total number of publications written about "Hepatocyte Growth Factor" by people in this website by year, and whether "Hepatocyte Growth Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 2 | 0 | 2 |
1996 | 1 | 1 | 2 |
1997 | 1 | 0 | 1 |
1998 | 2 | 1 | 3 |
1999 | 2 | 1 | 3 |
2000 | 1 | 1 | 2 |
2001 | 1 | 1 | 2 |
2002 | 2 | 2 | 4 |
2003 | 0 | 3 | 3 |
2004 | 2 | 2 | 4 |
2005 | 0 | 3 | 3 |
2006 | 0 | 3 | 3 |
2007 | 1 | 0 | 1 |
2008 | 1 | 0 | 1 |
2009 | 1 | 1 | 2 |
2010 | 2 | 3 | 5 |
2011 | 2 | 1 | 3 |
2012 | 1 | 5 | 6 |
2013 | 1 | 5 | 6 |
2014 | 3 | 2 | 5 |
2015 | 3 | 1 | 4 |
2016 | 2 | 3 | 5 |
2017 | 4 | 1 | 5 |
2018 | 2 | 1 | 3 |
2021 | 1 | 2 | 3 |
2023 | 0 | 1 | 1 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hepatocyte Growth Factor" by people in Profiles.
-
LIFR regulates cholesterol-driven bidirectional hepatocyte-neutrophil cross-talk to promote liver regeneration. Nat Metab. 2024 Sep; 6(9):1756-1774.
-
Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer. Cancer Lett. 2024 Apr 28; 588:216780.
-
Gene therapy for diabetic foot ulcers: Interim analysis of a randomised, placebo-controlled phase 3 study of VM202 (ENGENSIS), a plasmid DNA expressing two isoforms of human hepatocyte growth factor. Int Wound J. 2023 Nov; 20(9):3531-3539.
-
Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote virus detection and cancer. Cell Rep. 2021 08 03; 36(5):109491.
-
Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell. 2021 06 14; 39(6):866-882.e11.
-
Gene therapy for diabetic peripheral neuropathy: A randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor. Clin Transl Sci. 2021 05; 14(3):1176-1184.
-
Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer. Mol Cancer Ther. 2019 02; 18(2):399-412.
-
BMP7 Signaling in TGFBR2-Deficient Stromal Cells Provokes Epithelial Carcinogenesis. Mol Cancer Res. 2018 10; 16(10):1568-1578.
-
The role of HGF-MET pathway and CCDC66 cirRNA expression in EGFR resistance and epithelial-to-mesenchymal transition of lung adenocarcinoma cells. J Hematol Oncol. 2018 05 31; 11(1):74.
-
Adrenergic receptor agonists induce the differentiation of pluripotent stem cell-derived hepatoblasts into hepatocyte-like cells. Sci Rep. 2017 12 01; 7(1):16734.